Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial
M. Kreuter (Heidelberg, Germany), T. Maher (Los Angeles, California, United States of America), K. Ichikado (Kumamoto, Japan), J. Oldham (Sacramento, California, United States of America), C. Valenzuela (Madrid, Spain), H. Mueller (Biberach, Germany), K. Rohr (Ingelheim am Rhein, Germany), K. Flaherty (Ann Arbor, Michigan, United States of America)
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), T. Maher (Los Angeles, California, United States of America), K. Ichikado (Kumamoto, Japan), J. Oldham (Sacramento, California, United States of America), C. Valenzuela (Madrid, Spain), H. Mueller (Biberach, Germany), K. Rohr (Ingelheim am Rhein, Germany), K. Flaherty (Ann Arbor, Michigan, United States of America). Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial. 2974
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: